142 related articles for article (PubMed ID: 31533926)
1. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.
Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J
Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926
[TBL] [Abstract][Full Text] [Related]
2. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
[TBL] [Abstract][Full Text] [Related]
3. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Stein R; Goldenberg DM
Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody.
Urva SR; Yang VC; Balthasar JP
J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
Polli JR; Engler FA; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Blumenthal RD; Osorio L; Hayes MK; Horak ID; Hansen HJ; Goldenberg DM
Cancer Immunol Immunother; 2005 Apr; 54(4):315-27. PubMed ID: 15592930
[TBL] [Abstract][Full Text] [Related]
7. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts.
Urva SR; Balthasar JP
MAbs; 2010; 2(1):67-72. PubMed ID: 20081377
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice.
Beatty BG; O'Conner-Tressel M; Do T; Paxton RJ; Beatty JD
Cancer Res; 1990 Feb; 50(3 Suppl):846s-851s. PubMed ID: 2297732
[TBL] [Abstract][Full Text] [Related]
10. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies.
Primus FJ; Newell KD; Blue A; Goldenberg DM
Cancer Res; 1983 Feb; 43(2):686-92. PubMed ID: 6184152
[TBL] [Abstract][Full Text] [Related]
11. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.
Abuqayyas L; Balthasar JP
AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507
[TBL] [Abstract][Full Text] [Related]
13. Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen.
Shinmi D; Nakano R; Mitamura K; Suzuki-Imaizumi M; Iwano J; Isoda Y; Enokizono J; Shiraishi Y; Arakawa E; Tomizuka K; Masuda K
Cancer Med; 2017 Apr; 6(4):798-808. PubMed ID: 28211613
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
15. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody.
Pietersz GA; Patrick MR; Chester KA
J Nucl Med; 1998 Jan; 39(1):47-56. PubMed ID: 9443738
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies to carcinoembryonic antigen: a systematic analysis of antibody specificities by using related normal antigens and evidence for allotypic determinants on carcinoembryonic antigen.
Kuroki M; Kuroki M; Koga Y; Matsuoka Y
J Immunol; 1984 Oct; 133(4):2090-7. PubMed ID: 6206151
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen.
Gaida FJ; Fenger U; Wagener C; Neumaier M
Int J Cancer; 1992 May; 51(3):459-65. PubMed ID: 1592535
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: determination of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay.
Wagener C; Clark BR; Rickard KJ; Shively JE
J Immunol; 1983 May; 130(5):2302-7. PubMed ID: 6187848
[TBL] [Abstract][Full Text] [Related]
20. Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen.
Stewart LM; Young S; Watson G; Mather SJ; Bates PA; Band HA; Wilkinson RW; Ross EL; Snary D
Cancer Immunol Immunother; 1999 Feb; 47(6):299-306. PubMed ID: 10203059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
